Ovid Therapeutics (NASDAQ:OVID) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$6.27m (up by US$6.10m from 2Q 2024).
- Net loss: US$4.68m (down by 156% from US$8.37m profit in 2Q 2024).
- US$0.066 loss per share (down from US$0.12 profit in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ovid Therapeutics Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 62%.
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 63% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Ovid Therapeutics (3 make us uncomfortable) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Ovid Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.